PHOENIX, AZ, Jan. 12, 2012 /CNW/ - Compass Biotechnology's Board of
Directors has appointed Thomas F. Krucker as President of Operations.
For the past five years, Mr. Krucker has been working in the investment
banking industry and brings sophisticated financing, international
operations, and market knowledge to Compass. Mr. Krucker's wide ranging
and valuable expertise, from the automotive industry to the financial
markets, will greatly assist in Compass' domestic and international
sales efforts. Mr. Krucker has a J.D. from Pepperdine College of Law.
Mr. Krucker previously served with Toyota USA for 11 years and held
national positions as IR Director and Import Director for the USA
operations. During the course of his time with Toyota, his duties
included oversight for five divisions which reported to him, including
truck/rail transportation, ship routing, ten port authorities around
USA, treasury/customs responsibility for company, insurance/claims,
damage control for ocean rail vehicle delivery, truck assembly at all
ports, accessory and preparation at all ports.
Dr. Joseph Sinkule, CEO of Compass, said, "Compass is excited to recruit
someone with Tom's credentials as its President. Mr. Krucker has a
proven track-record of performance in creating value in small- and
mid-cap companies, and during his time with Toyota, was responsible for
the largest selling region in USA and for building a dealer network for
Toyota, which became the first imported vehicle nameplate to out-sell
and out-register all domestic car lines including Chevrolet, Ford, and
Chrysler. With international pharmaceutical product distribution and
sales as our end goal, Tom should be able to contribute significantly
to our current and future growth."
Garth Likes, Chairman of Compass stated, "Beyond his auto-industry
expertise, Mr.Krucker has sophisticated finance and equity market
knowledge and will be an invaluable asset to Compass Biotechnology,
ABOUT COMPASS BIOTECHNOLOGIES INC.
Compass Biotechnologies, Inc. is a publically-traded specialty pharmaceutical company (COBI:OB)
focused on building value in several key market areas - women's health,
hepatitis anti-viral drugs and prophylactic vaccines, recombinant
protein therapeutics called "biobetters", and cytokine reagents and
growth factor supplements for the cell culture and biotech
manufacturing industries. Products in these areas are being developed
within business units or franchises with majority ownership held by Compass Biotechnologies, Inc.
Forward Looking Statements
This news release contains "forward-looking statements", as that term is
defined in Section 27A of the United States Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
current report which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainty of financial estimates and projections, the competitive and
regulatory environments, stock market conditions, unforeseen technical
difficulties and our ongoing ability to operate a business and obtain
financing. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements. Although we believe that our beliefs, plans, expectations and intentions
contained in this current report are reasonable, there can be no
assurance that such beliefs, plans, expectations or intentions will
prove to be accurate. Investors should consult all of the information
set forth herein and should also refer to the risk factors disclosure
outlined in our quarterly reports on Form 10-Q and our other periodic
reports filed from time-to-time with the Securities and Exchange
Commission pursuant to the Securities Exchange Act.
SOURCE Compass Biotechnologies Inc.
For further information:
For further information and inquiries:
Compass Biotechnologies, Inc.
Dr. Joseph Sinkule
CEO and President
4105 N. 20th Street
Phoenix, AZ 85106 USA